Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 13.06 · gapped above the open, then crossed back over prior close. High/low 13.75 at 7:45 am ET, 12.92 at 3:30 pm ET.
Ultragenyx Pharmaceutical Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For the year ended December 31, 2024, 49% of our total revenues were generated by our collaboration partner KKC.”
$330M relationship
basisRARE fy2025 · closed 2025-12 $673M
FILING10-K0000950170-25-023312cik 0001515673
“For the year ended December 31, 2025, 45% of our total revenues were generated by our collaboration partner KKC.”
$303M relationship
basisRARE fy2025 · closed 2025-12 $673M
FILING10-K0001193125-26-057329
“Under the collaboration agreement, KKC manufactures and supplies Crysvita for sales in Latin American territories and we pay KKC a transfer price of 30% of net sales.”
$202M relationship
basisRARE fy2025 · closed 2025-12 $673M
FILING10-K0000950170-25-023312
“Under the collaboration agreement, KKC manufactures and supplies Crysvita, which is purchased by the Company for sales in Latin America and Turkey, and charges the Company a transfer price of 30 % of net sales.”
$202M relationship
basisRARE fy2025 · closed 2025-12 $673M
FILING10-K0000950170-25-023312
“The supply price to us for commercial sales of Crysvita in Latin America is 30% of net sales, which is higher than the typical cost of sales for companies focused on rare diseases.”
$202M relationship
basisRARE fy2025 · closed 2025-12 $673M
FILING10-K0001193125-26-057329
“Under the collaboration agreement, Regeneron supplies the product and charges the Company a transfer price from the low 20 % range up to 40 % on net sales, which is recognized as cost of sales in the Company's Statement of Operations.”
FILING10-K0000950170-25-023312cik 0001515673
“In December 2024, we entered into a manufacturing and supply agreement with Mereo where we are responsible for the supply of setrusumab to Mereo in the Mereo territory.”
FILING10-K0000950170-25-023312cik 0001515673
“Pursuant to the agreement, OMERS paid $500.0 million to us in consideration for the right to receive 30% of the future royalty payments due to us from KKC based on net sales of Crysvita in the U.S. and Canada under the terms of the KKC Collaboration Agreement.”
FILING10-K0000950170-25-023312cik 0001515673
“Pursuant to the agreement, RPI paid us $320.0 million in consideration for our right to receive royalty payments on the net sales of Crysvita in the European Union, or the EU, the UK, and Switzerland, effective January 1, 2020, under the terms of our Collaboration and License Agreement with Kyowa Kirin Co., Ltd., or KKC.”
FILING10-K0000950170-25-023312cik 0001515673
“The Evkeeza drug substance is manufactured by Regeneron at their manufacturing facility in Rensselaer, New York and the drug product is manufactured by Baxter Pharmaceutical Solutions, LLC at their manufacturing facility in Bloomington, Indiana.”
FILING10-K0001193125-26-057329cik 0001515673
“The drug product is manufactured by Patheon Pharma Services by ThermoFisher Scientific, our CDMO partner.”
FILING10-K0001193125-26-057329cik 0001515673
“The Company has a license agreement with REGENXBIO, Inc., or REGENX, for an exclusive, sublicensable, worldwide commercial license under certain intellectual property for preclinical and clinical research and development, and commercialization of drug therapies using REGENX's licensed patents for the treatment of OTC deficiency and GSD1a.”
FILING10-K0000950170-25-023312cik 0001515673
“We have entered into global licensing transactions with Ultragenyx for setrusumab and āshibio for vantictumab for further development and commercialization, under which we have retained commercial rights in Europe and the U.K.”
FILING10-K0001193125-26-115226cik 0001719714disclosed by MREO
“In March 2023, the Dojolvi drug product manufacturer Aenova Haupt Pharma Wolfratshausen GmbH notified us of their intent to close the facility by the end of 2023.”
FILING10-K0000950170-25-023312cik 0001515673
“Under the terms of this license agreement, as amended, BRI exclusively licensed to the Company its territories for certain intellectual property related to Dojolvi for the treatment of LC-FAOD.”
FILING10-K0000950170-25-023312cik 0001515673
“In October 2024, we filed a suit against Catalent Maryland, Inc. and Catalent Pharma Solutions, LLC (collectively, Catalent) in the Superior Court of the State of Delaware alleging that Catalent fraudulently mispresented its manufacturing capabilities and serially breached the terms of its manufacturing agreement with us.”
FILING10-K0001193125-26-057329cik 0001515673
“In October 2024, we filed a suit against Catalent Maryland, Inc. and Catalent Pharma Solutions, LLC (collectively, Catalent) in the Superior Court of the State of Delaware alleging that Catalent fraudulently mispresented its manufacturing capabilities and serially breached the terms of its manufacturing agreement with us.”
FILING10-K0001193125-26-057329cik 0001515673
“In October 2024, we filed a suit against Catalent Maryland, Inc. and Catalent Pharma Solutions, LLC (collectively, Catalent) in the Superior Court of the State of Delaware alleging that Catalent fraudulently mispresented its manufacturing capabilities and serially breached the terms of its manufacturing agreement with us.”
FILING10-K0001193125-26-057329cik 0001515673
“The pharmaceutical-grade drug substance for Dojolvi is manufactured by IOI Oleo GmbH, or IOI Oleo, in Germany under an exclusive worldwide supply agreement.”
FILING10-K0000950170-25-023312cik 0001515673
“The Mepsevii drug substance is manufactured by Rentschler Biopharma SE, or Rentschler, under non-exclusive commercial supply and services agreements.”
FILING10-K0000950170-25-023312cik 0001515673
“Under the terms of this license agreement, SLU granted the Company an exclusive worldwide license to make, have made, use, import, offer for sale, and sell therapeutics related to SLU's beta-glucuronidase product for use in the treatment of human diseases.”
FILING10-K0000950170-25-023312cik 0001515673
“In October 2020, the Company entered into a strategic Collaboration and License Agreement with Solid Biosciences Inc., or Solid, and received an exclusive license for any pharmaceutical product that expresses Solid's proprietary microdystrophin construct from AAV8 and variants thereof in clade E for use in the treatment of Duchenne muscular dystrophy and other diseases resulting from lack of functional dystrophin, including Becker muscular dystrophy.”
FILING10-K0000950170-25-023312cik 0001515673
“In addition, we have in-licensed various patents and patent applications owned by the University of Pennsylvania relating to our DTX301, and UX701 product candidates.”
FILING10-K0001193125-26-057329cik 0001515673
“In May 2022, the Company announced an exclusive License Agreement for the AAV gene therapy for UX111 with Abeona for the treatment of MPS IIIA.”
FILING10-K0000950170-25-023312cik 0001515673
Watchlist prices, news filtered to it, and its next report on your desk.
Ultragenyx Pharmaceutical Inc. has 20 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Ultragenyx Pharmaceutical Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
RARE (Ultragenyx Pharmaceutical Inc.) has 20 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: MREO −0.53%, in the health bundle.